Chuangyebang was informed that on April 25, Hefei Tiangang Immunopharmaceutical Co., Ltd., an invisible unicorn enterprise in the field of tumor immunotherapy, announced the completion of a Pre-A round of financing of several hundred million yuan. This round of financing was jointly led by Zhongke Chuangxing and Chuanggu Capital, and followed by many well-known investment institutions such as Hefei Industrial Investment, Yifeng Capital, Tiantu Investment, and Guoyuan Innovation Investment.
The funds raised in this round will be used to advance the development and registration of multiple product pipelines for tumor immunotherapy.
Established in 2020, Hefei Tiangang Immune Drug Co., Ltd. is a high-tech company focusing on the development of innovative immune drugs at the source. The company’s R&D team is one of the leaders in the global NK cell research field, and it has discovered and verified several NK cell immune checkpoints earlier in the world. The team’s research results have formed advantages in NK cell-targeted immunotherapy technology and product development.
The company has planned a series of technologies and products, covering: immune checkpoint inhibitors; dual/multifunctional antibody analogs; targeted antibody drugs; immunomodulators, etc. It has applied for 11 invention patents, and a number of products have completed preliminary research and development, and will soon enter the rapid development channel of product registration and listing. In addition, the company also has nearly 6,000 square meters of research and development sites including experimental animals, GMP-compliant recombinant protein preparation, and NK cell detection and analysis.
Xiao Weihua, co-founder of Hefei Tiangang Immune Drug Co., Ltd., said: Although the company has not been established for a long time, we are very confident to achieve the company’s strategic goals and become a leader, pioneer and promoter in the field of tumor immunotherapy. The successful completion of this financing has laid a more solid foundation for the company’s subsequent leap-forward development. The development of innovative biological drugs leads the overall pharmaceutical market with a rapid growth rate. We will adhere to the concept of “decoding natural immunity and leading pharmaceutical innovation in Hong Kong”, adhere to source innovation, focus on research and development, anchor goals, and continue to promote the development of immune-targeted drugs with conversion.
media coverage
China Investment Network Venture Capital
This article is reprinted from: https://readhub.cn/topic/8fuOm38qPr1
This site is for inclusion only, and the copyright belongs to the original author.